AbCellera Biologics Inc. (ABCL) vs BillionToOne, Inc. (BLLN)
A side-by-side comparison of AbCellera Biologics Inc. and BillionToOne, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ABCL
AbCellera Biologics Inc.
$13.14HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
BLLN
BillionToOne, Inc.
$100.96HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — ABCL vs BLLN
growth of $100 · dividends reinvested · last 1yABCL +193.8% (+193.8%/yr)BLLN +0.1% (+0.1%/yr)ABCL compounded faster over this window
ABCL BLLN
ABCL vs BLLN: by the numbers
- •BLLN is the larger company ($4.64B vs $4.01B market cap).
- •BLLN is profitable (8.43% net margin) while ABCL runs a net loss (-248.83%).
Metrics side by side
Valuation
| Metric | ABCL | BLLN |
|---|---|---|
| P/E ratio | N/A | 162.82 |
| Forward P/E | N/A | 127.11 |
| P/S ratio | 60.62 | 11.69 |
| P/B ratio | 4.48 | 8.65 |
| EV / EBITDA | N/A | 76.24 |
| FCF yield | N/A | 0.71% |
Profitability
| Metric | ABCL | BLLN |
|---|---|---|
| Gross margin | 61.64% | 71.27% |
| Operating margin | -288.98% | 10.90% |
| Net margin | -248.83% | 8.43% |
| ROE | -18.38% | 6.24% |
| ROIC | -17.95% | 6.39% |
Growth (annualized)
| Metric | ABCL | BLLN |
|---|---|---|
| Revenue CAGR (5Y) | -31.78% | N/A |
| Total return CAGR (5Y) | -3.57% | N/A |
Frequently asked
- Is ABCL or BLLN more profitable?
- BLLN runs the higher net margin — ABCL at -248.83% versus BLLN at 8.43%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.